- Male or female patients of at least 55 years of age with a clinical diagnosis of OA
who are expected to require daily prescription anti-inflammatory analgesic therapy
for arthritis symptom management and for whom either celecoxib or a nsNSAID is an
appropriate treatment option.
- GI ulcer hemorrhage or active GD ulceration less than 90 days prior to screening
- Patients with a history of myocardial infarction, unstable angina, ischemic or
hemorrhagic stroke, transient ischemic attack, previous revascularization procedure
to coronary, carotid, cerebral, renal, aortic or peripheral arterial vasculature.